



G1070-2

100 12 D 1 07/14/95 1202

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applications of:

Kenneth William Batchelor; Stephen Vernon Frye;  
George F. Dorsey, Jr.; Robert A. Mook, Jr.

Serial No.: 08/405,120

Group Art Unit:

Filed: March 16, 1995

Examiner:

For: ANDROSTENONE DERIVATIVE

Commissioner of Patents and Trademarks  
Washington, D.C. 20231

Dear Sir:


**LETTER OF EXPLANATION FOR CHANGE IN INVENTORSHIP**

The present application, 08/405,120 is a Continuation-in-Part of PCT/US94/10530.

Claims 6, 22, 23, 24 filed in this Continuation-in-Part application represent the work of two additional inventors, George F. Dorsey, Jr. and Robert A. Mook, Jr. Therefore, these two individuals should be deemed inventors with respect to the present application.

Please charge any fees associated with this Letter to Deposit Account No. 07-1392. A duplicate copy of this paper is attached for accounting purposes.

Respectfully submitted,

  
\_\_\_\_\_  
Charles E. Dadswell  
Attorney for Applicant  
Registration No. 35,851

Date: 14 June 1995

Glaxo Wellcome Inc.  
Five Moore Drive  
Research Triangle Park, NC 27709  
(919) 990-6983

**CERTIFICATE OF MAILING UNDER CFR 1.8**

I hereby certify that, on the date shown below, this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231 on 21 JUNE 1995.

  
\_\_\_\_\_  
Rosalie M. Germano